^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RAF265

    i
    Company:
    Novartis
    Drug class:
    BRAF inhibitor, VEGFR-2 inhibitor
    Related drugs:
    Apply
    A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (CHIR-265-MEL01) (NCT00304525)
    Phase 1/2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/19/2020
    Initiation :
    04/01/2006
    Primary completion :
    11/01/2013
    Completion :
    11/01/2013
    BRAF • RAS
    |
    BRAF mutation
    |
    RAF265
    MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations (NCT01352273)
    Phase 1
    Array Biopharma, now a wholly owned subsidiary ...
    Completed
    Last update posted :
    09/30/2020
    Initiation :
    06/01/2011
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Mektovi (binimetinib) • RAF265